Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marta Arimont

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Journal of Medicinal Chemistry|November 2, 2019
4-(3-Aminoazetidin-1-yl)pyrimidin-2-amines as High-Affinity Non-imidazole Histamine H<sub>3</sub> Receptor Agonists with in Vivo Central Nervous System ActivityGábor Wágner, Tamara A M Mocking, Marta Arimont, et al.
Biochemical Pharmacology|October 21, 2018
CXCR4-targeting nanobodies differentially inhibit CXCR4 function and HIV entryAnneleen Van Hout, Alex Klarenbeek, Vladimir Bobkov, et al.
Bioorganic & Medicinal Chemistry Letters|February 5, 2022
Synthesis and SAR of novel GPR39 agonists and positive allosteric modulatorsRussell Burley, Richard C Hewer, Martin Teall, et al.
Molecular Pharmacology|February 12, 2024
Pharmacological Characterization and Radiolabeling of VUF15485, a High-Affinity Small-Molecule Agonist for the Atypical Chemokine Receptor ACKR3Aurelien M Zarca, Ilze Adlere, Cristina P Viciano, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Journal of Medicinal Chemistry|November 2, 2019
4-(3-Aminoazetidin-1-yl)pyrimidin-2-amines as High-Affinity Non-imidazole Histamine H<sub>3</sub> Receptor Agonists with in Vivo Central Nervous System ActivityGábor Wágner, Tamara A M Mocking, Marta Arimont, et al.
Biochemical Pharmacology|October 21, 2018
CXCR4-targeting nanobodies differentially inhibit CXCR4 function and HIV entryAnneleen Van Hout, Alex Klarenbeek, Vladimir Bobkov, et al.
Bioorganic & Medicinal Chemistry Letters|February 5, 2022
Synthesis and SAR of novel GPR39 agonists and positive allosteric modulatorsRussell Burley, Richard C Hewer, Martin Teall, et al.
Molecular Pharmacology|February 12, 2024
Pharmacological Characterization and Radiolabeling of VUF15485, a High-Affinity Small-Molecule Agonist for the Atypical Chemokine Receptor ACKR3Aurelien M Zarca, Ilze Adlere, Cristina P Viciano, et al.
Pageof 2